Candaur Pharmaceuticals Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
as on 20-12-2024
- Paid Up Capital ₹ 2.20 M
as on 20-12-2024
- Company Age 19 Year, 6 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 1.64 Cr
as on 20-12-2024
- Revenue 61.20%
(FY 2023)
- Profit 45.24%
(FY 2023)
- Ebitda 151.16%
(FY 2023)
- Net Worth 11.26%
(FY 2023)
- Total Assets 9.34%
(FY 2023)
About Candaur Pharmaceuticals
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.20 M.
The company currently has active open charges totaling ₹1.64 Cr.
Manas Patnaik, Pragyan Patnaik, Supriya Mohanty, and One other member serve as directors at the Company.
- CIN/LLPIN
U24230MH2005PTC154284
- Company No.
154284
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
28 Jun 2005
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Thane, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Candaur Pharmaceuticals?
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Manas Patnaik  | Director | 01-Jul-2005 | Current |
| Pragyan Patnaik | Director | 01-Jul-2005 | Current |
| Supriya Mohanty | Director | 01-Jul-2015 | Current |
| Geetika Gupta | Additional Director | 16-Mar-2018 | Current |
Financial Performance of Candaur Pharmaceuticals.
Candaur Pharmaceuticals Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 61.2% increase. The company also saw a substantial improvement in profitability, with a 45.24% increase in profit. The company's net worth Soared by an impressive increase of 11.26%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Candaur Pharmaceuticals?
Unlock access to Candaur Pharmaceuticals's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 15 Mar 2014 | ₹1.64 Cr | Open |
How Many Employees Work at Candaur Pharmaceuticals?
Unlock and access historical data on people associated with Candaur Pharmaceuticals, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Candaur Pharmaceuticals, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Candaur Pharmaceuticals's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
